NCT05841030

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNRI

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 545 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
OTHER	No Intervention	There is no interventional treatment administered to the participants as a part of this study.

Timeline

• Start date: 2023-04-28
• Primary completion: 2026-03-13
• Completion: 2026-03-13
• First posted: 2023-05-03
• Last updated: 2026-03-12

Locations

95 sites across 11 countries: United States, Argentina, Brazil, Canada, France, Germany, Italy, South Korea, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study